Gold(I)-mediated inhibition of protein tyrosine phosphatases: A detailed in vitro and cellular study

Journal of Medicinal Chemistry

Volumn 51, Issue 15, 2008, Pages 4790-4795

  Krishnamurthy, Divya ^a,b   Karver, Mark R ^a,c   Fiorillo, Edoardo ^b   Orrú, Valeria ^b   Stanford, Stephanie M ^b   Bottini, Nunzio ^b   Barrios, Amy M ^a  

^a UNIVERSITY OF UTAH   (United States)

^b UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^c UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AURANOFIN; CARBENE; GOLD COMPLEX; PROTEIN TYROSINE PHOSPHATASE;

ANIMAL CELL; ARTICLE; DRUG SYNTHESIS; ENZYME ACTIVITY; ENZYME INHIBITION; HUMAN; HUMAN CELL; IMMUNOBLOTTING; IN VITRO STUDY; LEUKEMIA CELL LINE; MOUSE; NONHUMAN; POLYACRYLAMIDE GEL ELECTROPHORESIS; THYMOCYTE;

CELL LINE; ENZYME INHIBITORS; GOLD COMPOUNDS; HUMANS; HYDROGEN-ION CONCENTRATION; MOLECULAR STRUCTURE; PROTEIN TYROSINE PHOSPHATASES;

EID: 49449099348     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm800101w     Document Type: Article

References (32)

1. Alonso, A.; Sasin, J.; Bottini, N.; Friedberg, I.; Osterman, A.; Godzik, A.; Hunter, T.; Dixon, J.; Mustelin, T. Protein tyrosine phosphatases in the human genome. Cell 2004, 117, 699-711.
2. Zhang, Z. Y. Protein tyrosine phosphatases: structure and function, substrate specificity, and inhibitor development. Annu. Rev. Pharmacol. Toxicol. 2002, 42, 209-234.
3. Bialy, L.; Waldmann, H. Inhibitors of protein tyrosine phosphatases: next-generation drugs. Angew. Chem., Int. Ed. 2005, 44, 3814-3839.
4. Elchebly, M.; Payette, P.; Michaliszyn, E.; Cromlish, W.; Collins, S.; Loy, A. L.; Normandin, D.; Cheng, A.; Himms-Hagen, J.; Chan, C. C.; Ramachandran, C.; Gresser, M. J.; Tremblay, M. L.; Kennedy, B. P. Increased insulin sensitivity and obesity resistance in mice lacking the protein tyrosine phosphatase-1B gene. Science 1999, 283, 1544-1548.
5. Vang, T.; Congia, M.; Macis, M. D.; Musumeci, L.; Orru, V.; Zavattari, P.; Nika, K.; Tautz, L.; Tasken, K.; Cucca, F.; Mustelin, T.; Bottini, N. Autoimmune-associated lymphoid tyrosine phosphatase is a gain-of-function variant. Nat. Genet. 2005, 37, 1317-1319.
6. Bottini, N.; Vang, T.; Cucca, F.; Mustelin, T. Role of PTPN22 in type 1 diabetes and other autoimmune diseases. Semin. Immunol. 2006, 18, 207-213.
7. Forestier, J. Rheumatoid arthritis and its treatment by gold salts. J. Lab. Clin. Med. 1935, 20, 827-840.
8. Shaw, C. F. Gold-based therapeutic agents. Chem. Rev. 1999, 99, 2589-2600.
9. Brown, D. H.; Smith, W. E. The Chemistry of the Gold Drugs Used in the Treatment of Rheumatoid Arthritis. Chem. Soc. Rev. 1980, 9, 217-240.
10. Lorber, A.; Simon, T.; Leeb, J.; Peter, A.; Wilcox, S. Chrysotherapy. Suppression of immunoglobulin synthesis. Arthritis Rheum. 1978, 21, 785-791.
11. Hashimoto, K.; Whitehurst, C. E.; Matsubara, T.; Hirohata, K.; Lipsky, P. E. Immunomodulatory effects of therapeutic gold compounds. Gold sodium thiomalate inhibits the activity of T cell protein kinase C. J. Clin. Invest. 1992, 89, 1839-1848.
12. Chircorian, A.; Barrios, A. M. Inhibition of lysosomal cysteine proteases by chrysotherapeutic compounds: a possible mechanism for the antiarthritic activity of Au(I). Bioorg. Med. Chem. Lett. 2004, 14, 5113-5116.
13. Gunatilleke, S. S.; Barrios, A. M. Inhibition of lysosomal cysteine proteases by a series of Au(I) complexes: A detailed mechanistic investigation. J. Med. Chem. 2006, 49, 3933-3937.
14. de Fremont, P.; Scott, N. M.; Stevens, E. D.; Nolan, S. P. Synthesis and structural characterization of N-heterocyclic carbene gold(I) complexes. Organometallics 2005, 24, 2411-2418.
15. Baker, M. V.; Barnard, P. J.; Brayshaw, S. K.; Hickey, J. L.; Skelton, B. W.; White, A. H. Synthetic, structural and spectroscopic studies of (pseudo)halo(1,3-di-tert-butylimidazol-2-ylidine)gold complexes. J. Chem. Soc., Dalton Trans. 2005, 37-43.
16. Baker, M. V.; Barnard, P. J.; Berners-Price, S. J.; Brayshaw, S. K.; Hickey, J. L.; Skelton, B. W.; White, A. H. Cationic, linear Au(I) N-heterocyclic carbene complexes: synthesis, structure and antimitochondrial activity. J. Chem. Soc., Dalton Trans. 2006, 3708-3715.
17. Wang, H. M. J.; Chen, C. Y. L.; Lin, I. J. B. Synthesis, structure, and spectroscopic properties of gold(I)-carbene complexes. Organometallics 1999, 18, 1216-1223.
18. Barnard, P. J.; Baker, M. V.; Berners-Price, S. J.; Day, D. A. Mitochondrial permeability transition induced by dinuclear gold(I)-carbene complexes: potential new antimitochondrial antitumour agents. J. Inorg. Biochem. 2004, 98, 1642-1647.
19. Barnard, P. J.; Ho, A. Y. Y.; Baker, M. V.; Day, D. A.; Berners-Price, S. J. Gold-Phosphine and Gold-Carbene complexes as potential mitochontrial targeting antitumor agents. Proc. Gold 2003, 1-5.
20. Wang, Q.; Janzen, N.; Ramachandran, C.; Jirik, F. Mechanism of inhibition of protein-tyrosine phosphatases by disodium aurothiomalate. Biochem. Pharmacol. 1997, 54, 703-711.
21. Haider, J.; Kunz, K.; Scholz, U. Highly selective copper-catalyzed monoarylation of aniline. Adv. Synth. Catal. 2004, 346, 717-722.
22. Sutton, B. M.; Walz, D. T.; Mcgusty, E.; Dimartino, M. J. Oral Gold: Antiarthritic Properties of Alkylphosphinegold Coordination Complexes. J. Med. Chem. 1972, 15, 1095-1098.
23. Mustelin, T.; Tautz, L.; Page, R. Structure of the hematopoietic tyrosine phosphatase (HePTP) catalytic domain: structure of a KIM phosphatase with phosphate bound at the active site. J. Mol. Biol. 2005, 354, 150-163.
24. Clipstone, N. A.; Crabtree, G. R. Identification of calcineurin as a key signalling enzyme in T-lymphocyte activation. Nature 1992, 357, 695-697.
25. Denu, J. M.; Dixon, J. E. Protein tyrosine phosphatases: mechanisms of catalysis and regulation. Curr. Opin. Chem. Biol. 1998, 2, 633-641.
26. Fricker, S. P. Medicinal uses of gold compounds: past, present, and future. Gold Bull. 1996, 29, 53-60.
27. Galic, S.; Hauser, C.; Kahn, B. B.; Haj, F. G.; Neel, B. G.; Tonks, N. K.; Tiganis, T. Coordinated regulation of insulin signaling by the protein tyrosine phosphatases PTP1B and TCPTP. Mol. Cell. Biol. 2005, 25, 819-829.
28. Yu, X.; Sun, J. P.; He, Y.; Guo, X.; Liu, S.; Zhou, B.; Hudmon, A.; Zhang, Z. Y. Structure, inhibitor and regulatory mechanism of Lyp, a lymphoid-specific tyrosine phosphatase implicated in autoimmune diseases. Proc. Natl. Acad. Sci. U.S.A. 2007, 104, 19767-19772.
29. Xie, Y.; Liu, Y.; Gong, G.; Rinderspacher, A.; Deng, S. X.; Smith, D. H.; Toebben, U.; Tzilianos, E.; Branden, L.; Vidovic, D.; Chung, C.; Schurer, S.; Tautz, L.; Landry, D. W. Discovery of a novel submicromolar inhibitor of the lymphoid specific tyrosine phosphatase. Bioorg. Med. Chem. Lett. 2008, 18, 2840-2844.
30. Mustelin, T.; Alonso, A.; Bottini, N.; Huynh, H.; Rahmouni, S.; Nika, K.; Louis-dit-Sully, C.; Tautz, L.; Togo, S. H.; Bruckner, S.; Mena-Duran, A. V.; al-Khouri, A. M. Protein tyrosine phosphatases in T cell physiology. Mol. Immunol. 2004, 41, 687-700.
31. Mustelin, T.; Rahmouni, S.; Bottini, N.; Alonso, A. Role of protein tyrosine phosphatases in T cell activation. Immunol. Rev. 2003, 191, 139-147.
32. Wu, J.; Katrekar, A.; Honigberg, L. A.; Smith, A. M.; Conn, M. T.; Tang, J.; Jeffery, D.; Mortara, K.; Sampang, J.; Williams, S. R.; Buggy, J.; Clark, J. M. Identification of substrates of human protein-tyrosine phosphatase PTPN22. J. Biol. Chem. 2006, 281, 11002-11010.